Novartis to speed up bid for MS drug approval, changes target

ZURICH (Reuters) - Novartis said on Tuesday it would accelerate its bid to win approval for its experimental multiple sclerosis (MS) drug BAF312 and said it was now targeting patients at an earlier stage of the neurological disease.